Evidence map›Paper›PMID 42594274›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Histone H3K27M variants determine myeloid subset dependencies and immune reprogramming in diffuse midline glioma.

Montserrat Puigdelloses Vallcorba, Kavita Rawat, Nishant Soni, Angela DiMauro, Jacqueline D Chu, Wes Thomason, Glaucia C Furtado, Maya Strahl, Junyan Wu, Tanvi Joshi and 7 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Montserrat Puigdelloses Vallcorba *Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0001-6011-1755
Kavita Rawat *Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-9498-9723
Nishant Soni *Department of Genetics and Genomic Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-1567-0712
Angela DiMauro *Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0009-0009-9313-8693
Jacqueline D Chu *Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Wes ThomasonDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Glaucia C FurtadoLipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Maya StrahlLipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0001-6244-1766
Junyan WuDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Tanvi JoshiDepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0001-7436-4673
Angelo AngioneDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0001-7713-5833
Gonzalo PiñeroDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Oren J BecherDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-4016-8492
James L RossDepartment of Neuroscience, University of Virginia School of Medicine, Charlottesville, VA 22908.
Alexander M TsankovDepartment of Genetics and Genomic Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Sergio A LiraLipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-6742-3089
Dolores HambardzumyanDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-1975-4665

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
The role of Myeloid cells in pediatric-high grade gliomasR01CA258636 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BECHER, OREN JOSH, HAMBARDZUMYAN, DOLORES · 2022 to 2025
$2.7M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Human-mouse platform for data-driven patient stratification, target discovery, and validation in GBMR01CA308411 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Alexander Minchev Tsankov · 2026 to 2026
$683k
HHS | NIH | National Cancer Institute (NCI) R01CA258636HHS | NIH | National Cancer Institute (NCI) R01CA308411NCATS NIH HHS UL1 TR004419NCI NIH HHS R01 CA258636NCI NIH HHS R01 CA308411NIH HHS S10 OD030463
6 · The paper itself

Abstract

Diffuse midline gliomas (DMGs) are highly aggressive, WHO grade 4 glial tumors that arise in midline central nervous system structures and are defined by K27M mutations in histone H3 genes. These K27M mutations shape intratumoral myeloid cell composition in DMG. In H3.1K27M DMGs, genetic ablation of monocyte recruitment reshapes the tumor microenvironment (TME) by reducing monocyte-derived macrophages (MDMs) and increasing microglia and neutrophil presence, with overall survival remaining unchanged, indicating compensatory myeloid remodeling is occurring. Here, by using CRISPR/Cas9-based genome editing, we generated a mouse model deficient for CCR1/CCR2/CCR3/CCR5 (Δ1235). Using this strain, we effectively abolished monocyte and MDM infiltration and reversed compensatory recruitment of CCR1+ neutrophils. Abolishing MDMs in tumors skewed remaining neutrophils and microglia toward a homeostatic state, reduced expression of immune checkpoint molecules on T cells, and extended the survival of H3.1K27M DMG-bearing mice. In contrast, H3.3K27M DMG showed independence from MDM recruitment, suggesting reliance on other TME-driven signaling. Last, H3.1K27M DMGs exhibited reduced microglia presence and a dose-dependent increase in MDM infiltration postirradiation. MDM depletion did not further enhance radiation efficacy, potentially due to compensatory recruitment of classical neutrophils. Collectively, these data reveal histone mutation-specific myeloid dependencies in DMG, highlighting MDM-independent mechanisms in H3.3K27M tumors and MDM-dependent pathways in H3.1K27M tumors.

Indexed as

Brain NeoplasmsGliomaHistonesMyeloid CellsAnimalsMacrophagesMiceMicrogliaMutationNeutrophilsTumor MicroenvironmentHistonesGliomamicrogliamonocyteneutrophilpediatric

Identifiers

PMID42594274
PMCPMC13486528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.